|

TR-002 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Bisaminoquinoline Derivative

Pipeline

Phase 1: 1

Top Sponsors

  • University of California, Davis1

Indications

  • Unresectable Pancreatic Adenocarcinoma1
  • Refractory Pancreatic Adenocarcinoma1
  • Metastatic Pancreatic Adenocarcinoma1
  • Stage IV Pancreatic Cancer AJCC v81
  • Stage III Pancreatic Cancer AJCC v81

Sacramento, California1 trial

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

University of California Davis Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.